Second-Line Therapy for SCLC - Baseline Assessment
Associate Director, Cancer Care Equity Program
Assistant Professor of Medicine, Dana-Farber Cancer Institute
Harvard Medical School
Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She completed her internal medicine residency at Rutgers New Jersey Medical School and her fellowship at the Mayo Clinic in Rochester, Minnesota, where she served as chief fellow from 2018 to 2019.
Dr. Florez's clinical interests include targeted therapies for lung cancer and addressing the unique aspects of survivorship in women with lung cancer. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Beyond her clinical work, Dr. Florez is a leading researcher in cancer health disparities and has been recognized for her efforts to improve equitable access to high-quality cancer care for underserved populations.
In 2025, Dr. Florez was named a Health Equity Champion by the Boston Business Journal in their Innovators in Healthcare program, acknowledging her transformative work on initiatives such as SHAWL, FhINCH, and EQUAL, which aim to enhance access to care for underserved communities.
Dr. Florez also founded the Florez Lab in 2019, focusing on lung cancer research, social justice issues in medicine, and medical education. The lab aims to create a welcoming environment for medical trainees from historically underrepresented groups while improving care for vulnerable populations.
Clinical Director, Lowe Center for Thoracic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Harvard Medical School
Dr. Julia K. Rotow is a thoracic medical oncologist at Dana-Farber Cancer Institute and the Clinical Director of the Lowe Center for Thoracic Oncology. She is also an Assistant Professor of Medicine at Harvard Medical School.
Dr. Rotow completed her medical degree at the David Geffen School of Medicine at UCLA, followed by an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at the University of California, San Francisco.
Her clinical and research interests focus on developing targeted therapies and immunotherapies for oncogene-driven lung cancers, with a particular emphasis on addressing central nervous system metastases.
Beyond her clinical work, Dr. Rotow is an active researcher in the field of lung cancer treatment and is dedicated to advancing care for patients with advanced-stage disease. She is affiliated with both Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she continues to contribute to patient care and research.
